The Insider, James Kim Picked up 419 Shares of Central Valley Community Bancorp (CVCY); Chemocentryx (CCXI) Sellers Increased By 0.99% Their Shorts

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

Chemocentryx Inc (NASDAQ:CCXI) had an increase of 0.99% in short interest. CCXI’s SI was 2.53M shares in December as released by FINRA. Its up 0.99% from 2.50M shares previously. With 136,800 avg volume, 19 days are for Chemocentryx Inc (NASDAQ:CCXI)’s short sellers to cover CCXI’s short positions. The SI to Chemocentryx Inc’s float is 10.72%. The stock increased 1.53% or $0.16 during the last trading session, reaching $10.63. About 112,194 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 51.30% since December 4, 2017 and is uptrending. It has outperformed by 35.68% the S&P500. Some Historical CCXI News: 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA

Investors sentiment decreased to 1.19 in 2018 Q2. Its down 0.10, from 1.29 in 2018Q1. It dived, as 3 investors sold Central Valley Community Bancorp shares while 24 reduced holdings. 7 funds opened positions while 25 raised stakes. 5.92 million shares or 2.05% more from 5.81 million shares in 2018Q1 were reported. Morgan Stanley owns 37,849 shares for 0% of their portfolio. 150 were reported by North Star Management Corporation. Manufacturers Life Ins The holds 0% in Central Valley Community Bancorp (NASDAQ:CVCY) or 9,447 shares. Geode Limited Co reported 103,565 shares stake. Bnp Paribas Arbitrage reported 0% of its portfolio in Central Valley Community Bancorp (NASDAQ:CVCY). Menta Capital Limited Liability Co has invested 0.15% in Central Valley Community Bancorp (NASDAQ:CVCY). Bessemer Gp Incorporated has invested 0% of its portfolio in Central Valley Community Bancorp (NASDAQ:CVCY). State Street invested in 172,520 shares. Clarivest Asset Mngmt holds 0.01% or 39,000 shares in its portfolio. Jacobs Levy Equity Mngmt holds 0.01% in Central Valley Community Bancorp (NASDAQ:CVCY) or 26,391 shares. Acadian Asset Ltd Liability accumulated 17,162 shares. Dalton Greiner Hartman Maher And Com holds 65,338 shares. The Georgia-based Invesco has invested 0% in Central Valley Community Bancorp (NASDAQ:CVCY). 3,339 were accumulated by Citigroup. State Of Wisconsin Inv Board has invested 0.01% in Central Valley Community Bancorp (NASDAQ:CVCY).

More notable recent Central Valley Community Bancorp (NASDAQ:CVCY) news were published by: Nasdaq.com which released: “CVCY vs. COLB: Which Stock Is the Better Value Option? – Nasdaq” on November 27, 2018, also Nasdaq.com with their article: “Here’s Why Zions (ZION) is a Solid Investment Option Now – Nasdaq” published on November 26, 2018, Nasdaq.com published: “Central Valley Community Bancorp (CVCY) Ex-Dividend Date Scheduled for November 01, 2018 – Nasdaq” on October 31, 2018. More interesting news about Central Valley Community Bancorp (NASDAQ:CVCY) were released by: Nasdaq.com and their article: “Central Valley Community Bancorp Sees Hammer Chart Pattern: Time to Buy? – Nasdaq” published on November 23, 2018 as well as Zacks.com‘s news article titled: “CVCY or CVBF: Which Is the Better Value Stock Right Now? – Zacks.com” with publication date: June 19, 2018.

The stock decreased 0.39% or $0.08 during the last trading session, reaching $20.34. About 588 shares traded. Central Valley Community Bancorp (NASDAQ:CVCY) has risen 8.38% since December 4, 2017 and is uptrending. It has underperformed by 7.24% the S&P500. Some Historical CVCY News: 26/04/2018 – WA State Auditor: Central Valley Ambulance Authority Financial 4/26/2018 – 4/26/2018; 16/04/2018 – Moody’s Assigns Aa2 Underlying, Aa1 Enhanced To Spokane County S.D. 356 (Central Valley), Wa’s Go Bonds; 19/04/2018 – Central Valley Community Raises Dividend to 7c; 26/03/2018 – DEFH: Notice and Agenda for Public Hearing on Civil Rights in California’s Central Valley April 20, 2018 10:00 a.m; 18/04/2018 – Central Valley Community 1Q EPS 38c; 10/04/2018 – Fresno NBC Affiliate, KSEE 24, to Produce California Gubernatorial Debate LIVE in the Central Valley, Broadcast Statewide; 19/04/2018 – CENTRAL VALLEY COMMUNITY BANCORP CVCY.O SETS REGULAR QUARTERLY CASH DIVIDEND OF $0.07/SHR; 18/04/2018 – CENTRAL VALLEY COMMUNITY BANCORP – AS PER SALE AND ASSUMPTION AGREEMENT, BAC COMMUNITY BANK WILL PURCHASE FROM CO CERTAIN DEPOSITS OF TRACY OFFICE; 20/04/2018 – DJ Central Valley Community Bancorp, Inst Holders, 1Q 2018 (CVCY); 19/04/2018 – Central Valley Community Bancorp Increases Quarterly Cash Dividend

Since September 4, 2018, it had 3 insider buys, and 0 selling transactions for $17,515 activity. 14 Central Valley Community Bancorp (NASDAQ:CVCY) shares with value of $273 were bought by Ford James M. The insider Kim James J bought $7,663.

Analysts await Central Valley Community Bancorp (NASDAQ:CVCY) to report earnings on January, 23. They expect $0.40 earnings per share, up 42.86% or $0.12 from last year’s $0.28 per share. CVCY’s profit will be $5.52 million for 12.71 P/E if the $0.40 EPS becomes a reality. After $0.42 actual earnings per share reported by Central Valley Community Bancorp for the previous quarter, Wall Street now forecasts -4.76% negative EPS growth.

Central Valley Community Bancorp operates as the bank holding firm for the Central Valley Community Bank that provides various commercial banking services to individuals, and small and middle market businesses in the central valley area of California. The company has market cap of $280.62 million. The Company’s deposit products include interest-bearing deposits comprising savings, NOW, and money market accounts, as well as time certificates of deposit; and non-interest bearing demand deposits. It has a 17.22 P/E ratio. The firm also provides commercial and industrial loans, as well as loans secured by crop production and livestock; owner occupied, real estate construction and other land, agricultural and commercial real estate, and other real estate loans; and equity loans and lines of credit, and consumer and installment loans.

As announced in the SEC, a public report for the trade of 419 shares of Central Valley Community Bancorp by James Kim was filled. James Kim now serves as a EXECUTIVE VICE PRESIDENT of the public company. The public document was filled on 04/12/2018. The mentioned shares were obtained at average $18.3 per every share, and are valued at $7,674 U.S. Dollars. James Kim currently possess 0.02% of the company’s total market cap with ownership of 3,193 shares. 

Since June 26, 2018, it had 0 buys, and 7 selling transactions for $88.11 million activity. KANAYA SUSAN M also sold $1,410 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) on Friday, June 29. $85.85M worth of ChemoCentryx, Inc. (NASDAQ:CCXI) was sold by GLAXOSMITHKLINE PLC on Tuesday, October 16. 10,857 shares were sold by Schall Thomas J., worth $152,028 on Thursday, June 28. 30,237 ChemoCentryx, Inc. (NASDAQ:CCXI) shares with value of $332,779 were sold by Cappel Markus J..

Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. ChemoCentryx has $20 highest and $12.5 lowest target. $16.38’s average target is 54.09% above currents $10.63 stock price. ChemoCentryx had 4 analyst reports since June 28, 2018 according to SRatingsIntel. The firm earned “Neutral” rating on Tuesday, August 14 by JP Morgan. Canaccord Genuity maintained it with “Buy” rating and $20 target in Monday, November 12 report.

Investors sentiment increased to 1.59 in Q2 2018. Its up 0.59, from 1 in 2018Q1. It is positive, as 11 investors sold ChemoCentryx, Inc. shares while 28 reduced holdings. 28 funds opened positions while 34 raised stakes. 26.37 million shares or 8.85% more from 24.22 million shares in 2018Q1 were reported. Moreover, Employees Retirement Systems Of Ohio has 0.01% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 117,524 shares. Strs Ohio accumulated 60,200 shares or 0% of the stock. Northern Trust, Illinois-based fund reported 263,766 shares. Ameritas Invest Ptnrs Inc reported 2,120 shares. The New York-based New York State Common Retirement Fund has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Fernwood Invest Mgmt Lc invested 0.07% in ChemoCentryx, Inc. (NASDAQ:CCXI). Deutsche Bank Ag owns 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 76,598 shares. Los Angeles Cap Management Equity Rech, a California-based fund reported 23,932 shares. Qs Investors Ltd owns 643 shares. Metropolitan Life Communication holds 8,715 shares. Keybank National Association Oh has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). New York-based Element Cap Mngmt Ltd Llc has invested 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI). Pnc Fincl Group holds 74 shares or 0% of its portfolio. 197,230 were accumulated by Jpmorgan Chase Co. Sei Invs has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI).

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $537.09 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 43.04 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Globenewswire.com which released: “ChemoCentryx Reports Third Quarter 2018 Financial Results and Recent Highlights – GlobeNewswire” on November 08, 2018, also Nasdaq.com with their article: “New Research Coverage Highlights Ralph Lauren, CECO Environmental, PRA Group, ChemoCentryx, SunCoke Energy Partners, and Delek US — Consolidated Revenues, Company Growth, and Expectations for 2018 – Nasdaq” published on November 27, 2018, Nasdaq.com published: “ChemoCentryx’s Novel Small Molecule Antagonists of Checkpoint Inhibitors and Chemokine Receptors to be Presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference – Nasdaq” on November 29, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Seekingalpha.com and their article: “ChemoCentryx 2018 Q3 – Results – Earnings Call Slides – Seeking Alpha” published on November 08, 2018 as well as Seekingalpha.com‘s news article titled: “ChemoCentryx (CCXI) CEO Thomas Schall on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: November 08, 2018.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *